Synta Pharmaceuticals (SNTA) Reports On Progress With Lead HDC Compounds At IASLC Conference
2/24/2014 6:43:06 AM
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) today reported on progress with lead compounds from its Hsp90-Inhibitor Drug Conjugate (HDC) platform at the IASLC 14th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting in Santa Monica, California. The new compounds, consisting of an Hsp90-inhibitor conjugated with SN-38 (HDC SN-38) and an Hsp90-inhibitor conjugated with docetaxel (HDC docetaxel), demonstrated proof of principle in multiple preclinical cancer models.
Help employers find you! Check out all the jobs and post your resume.
comments powered by